---
title: "華潤醫藥旗下 DC6001 片及甲硝唑凝膠獲批臨牀及上市"
description: "華潤醫藥宣佈，其附屬公司北京雙鶴潤創科技的 DC6001 片獲得國家藥監局的臨牀試驗批准，用於治療青少年遺傳性黃斑變性疾病。同時，華潤三九醫藥股份的甲硝唑凝膠獲准上市，適用於多種皮膚炎症的局部治療。"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/270693578.md"
published_at: "2025-12-24T06:12:19.000Z"
---

# 華潤醫藥旗下 DC6001 片及甲硝唑凝膠獲批臨牀及上市

> 華潤醫藥宣佈，其附屬公司北京雙鶴潤創科技的 DC6001 片獲得國家藥監局的臨牀試驗批准，用於治療青少年遺傳性黃斑變性疾病。同時，華潤三九醫藥股份的甲硝唑凝膠獲准上市，適用於多種皮膚炎症的局部治療。

華潤醫藥 (03320.HK) 公佈，集團旗下附屬北京雙鶴潤創科技收到國家藥監局頒發的 DC6001 片《藥物臨牀試驗批准通知書》。同時，集團旗下華潤三九醫藥股份的甲硝唑凝膠獲得國家藥監局批准上市。

DC6001 片擬用於青少年遺傳性黃斑變性疾病 (Stargardt 病)。

甲硝唑是一種廣譜抗菌藥物，可以高效殺滅和抑制厭氧菌，具有顯着的抗炎與免疫調節作用，適用於炎症性丘疹、膿皰瘡、酒渣鼻紅斑的局部治療，也是國內外玫瑰痤瘡指南推薦的一線用藥，而凝膠劑具有良好的滲透性，膚感清爽，使用方便，更好地滿足患者對皮膚局部治療用藥的需求。

### Related Stocks

- [03320.HK - 華潤醫藥](https://longbridge.com/zh-HK/quote/03320.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Shanghai Fosun Pharma Says Drug Registration Application Of Tetracaine Hydrochloride Gel Accepted By NMPA | Shanghai Fosun Pharmaceutical Group Co Ltd :DRUG REGISTRATION APPLICATION OF TETRACAINE HYDROCHLORIDE GEL ACCEPTED BY CH | [Link](https://longbridge.com/zh-HK/news/275438926.md) |
| Why Keloids Keep Growing According to Dr. Mendez and Dr. Salloum | Keloid scars, which affect millions globally, are caused by an overactive healing response leading to excessive collagen | [Link](https://longbridge.com/zh-HK/news/276061524.md) |
| DC Water provides updates 1 month after massive sewage spill into Potomac | DC Water provided updates to the D.C. council regarding the sewage spill into the Potomac River, which resulted from the | [Link](https://longbridge.com/zh-HK/news/276242777.md) |
| Tennis-Badosa slams online 'disrespect' after Dubai injury retirement | Paula Badosa criticized online comments after retiring from her match at the Dubai Tennis Championships due to a thigh i | [Link](https://longbridge.com/zh-HK/news/276203567.md) |
| Will China Literature Turn The Page? | China Literature Ltd. expects a net loss of up to 850 million yuan for last year, primarily due to a 1.8 billion yuan go | [Link](https://longbridge.com/zh-HK/news/276113491.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。